Larimar Therapeutics, Inc. 8-K

What Happened

• Larimar Therapeutics, Inc. (LRMR) filed a Current Report on Form 8-K on March 9, 2026, under Item 8.01 (Other Events) to disclose that it posted an updated corporate presentation on its website. The presentation (Exhibit 99.1), dated March 9, 2026, will be used by company representatives in meetings with investors, analysts and other parties.
• The 8-K was signed by Carole S. Ben-Maimon, M.D., President and Chief Executive Officer, on March 9, 2026.

Key Details

• Filing date: March 9, 2026 (Form 8-K).
• Document attached: Exhibit 99.1 — Larimar Therapeutics, Inc. Corporate Presentation dated March 9, 2026.
• Purpose: Presentation to be used in investor/analyst meetings; posted on the company website.
• No financial results, management changes, or material transactions were disclosed in this filing.

Why It Matters

• This is an informational filing indicating Larimar updated its investor materials; it does not report earnings, a merger, or executive changes. Investors should view it as routine investor-relations activity that may include refreshed company strategy, program updates, or milestones but does not, by itself, change the company’s financial or operational disclosures.
• If you follow Larimar, review the posted presentation for any new program or pipeline details the company highlights, but rely on separate filings for formal financial or material event disclosures.